Skip to main content
SpringerLink
Log in

Overview of Gastrointestinal Neuroendocrine Tumours

  • Chapter
Neuroendocrine Tumours

  • 1659 Accesses

Abstract

There are vast differences in terminology, classification and grading of gastrointestinal neuroendocrine tumours (NETs); mostly the organ or tissue of origin is considered for nomenclature and grading. GI-NETs are relatively rare, accounting for approximately 0.5 % of all human cancers. Embryologically NETs are divided into three categories as described by William and Sandler: foregut carcinoids (lung, stomach, duodenum, upper jejenum and pancreas), midgut carcinoids (lower jejenum, ileum, appendix, caecum) and hindgut carcinoids (colon and rectum). GI-NETs are those arising at the oesophagus, stomach, bile ducts and gall bladder, duodenum, jejunum, appendix, colon and rectum. Oesophageal NETs are extremely rare. Gastric NETs are divided into four groups based on clinicopathological features as type 1, type 2, type 3 and type 4. This classification has also prognostic and management implications. Primary duodenal NETs account for less than 2 % of all gastrointestinal NETs. They are relatively benign lesions with slow growth pattern and low metastatic potential. The ileum and appendix are the most common sites of NETs in the West, while colorectal NETs are relatively more common in the East. As for the classification, management also depends on the primary site, grade and the stage of the disease. In localised disease, surgery is the mainstay of treatment. In symptomatic cases, somatostatin analogues are effective. Liver-directed therapies and systemic cytotoxic drugs and targeted agents can be used in selected cases.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Yao JC, Hassan M, Phan A et al (2008) One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26:3063–3072

    Article  PubMed  Google Scholar 

  2. Modlin IM, Oberg K, Chung DC et al (2008) Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 9:61–72

    Article  CAS  PubMed  Google Scholar 

  3. Crocetti E, Paci E (2003) Malignant carcinoids in the USA, SEER 1992–1999. An epidemiological study with 6830 cases. Eur J Cancer Prev 12:191–194

    Article  CAS  PubMed  Google Scholar 

  4. Taal BG, Visser O (2004) Epidemiology of neuroendocrine tumours. Neuroendocrinology 80(Suppl 1):3–7

    Article  CAS  PubMed  Google Scholar 

  5. Karpathakis A, Caplin M, Thirlwell C (2012) Hitting the target: where do molecularly targeted therapies fit in the treatment scheduling of neuroendocrine tumours? Endocr Relat Cancer 19:R73–R92

    Article  CAS  PubMed  Google Scholar 

  6. Oberg K (2012) Neuroendocrine tumors of the digestive tract: impact of new classifications and new agents on therapeutic approaches. Curr Opin Oncol 24:433–440

    Article  PubMed  Google Scholar 

  7. Steinmuller T, Kianmanesh R, Falconi M et al (2008) Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 87:47–62

    Article  PubMed  Google Scholar 

  8. Williams ED, Sandler M (1963) The classification of carcinoid tumours. Lancet 1:238–239

    Article  CAS  PubMed  Google Scholar 

  9. Kloppel G, Rindi G, Anlauf M et al (2007) Site-specific biology and pathology of gastroenteropancreatic neuroendocrine tumors. Virchows Arch 451(Suppl 1):S9–S27

    Article  PubMed  Google Scholar 

  10. Brenner S, Heimlich H, Widman M (1969) Carcinoid of esophagus. N Y State J Med 69:1337–1339

    CAS  PubMed  Google Scholar 

  11. Ready AR, Soul JO, Newman J et al (1989) Malignant carcinoid tumour of the oesophagus. Thorax 44:594–596

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  12. Li QL, Zhang YQ, Chen WF et al (2012) Endoscopic submucosal dissection for foregut neuroendocrine tumors: an initial study. World J Gastroenterol 18:5799–5806

    Article  PubMed Central  PubMed  Google Scholar 

  13. Lindberg GM, Molberg KH, Vuitch MF et al (1997) Atypical carcinoid of the esophagus: a case report and review of the literature. Cancer 79:1476–1481

    Article  CAS  PubMed  Google Scholar 

  14. Chen WF, Zhou PH, Li QL et al (2012) Clinical impact of endoscopic submucosal dissection for gastric neuroendocrine tumors: a retrospective study from mainland China. ScientificWorldJournal 2012:869769

    PubMed Central  PubMed  Google Scholar 

  15. Jianu CS, Lange OJ, Viset T et al (2012) Gastric neuroendocrine carcinoma after long-term use of proton pump inhibitor. Scand J Gastroenterol 47:64–67

    Article  CAS  PubMed  Google Scholar 

  16. Bordi C (1999) Gastric carcinoids. Ital J Gastroenterol Hepatol 31(Suppl 2):S94–S97

    PubMed  Google Scholar 

  17. Li TT, Qiu F, Qian ZR et al (2014) Classification, clinicopathologic features and treatment of gastric neuroendocrine tumors. World J Gastroenterol 20:118–125

    Article  PubMed Central  PubMed  Google Scholar 

  18. Plockinger U (2007) Diagnosis and treatment of gastric neuroendocrine tumours. Wien Klin Wochenschr 119:570–572

    Article  PubMed  Google Scholar 

  19. Kidd M, Siddique ZL, Drozdov I et al (2010) The CCK(2) receptor antagonist, YF476, inhibits Mastomys ECL cell hyperplasia and gastric carcinoid tumor development. Regul Pept 162:52–60

    Article  CAS  PubMed  Google Scholar 

  20. Fossmark R, Sordal O, Jianu CS et al (2012) Treatment of gastric carcinoids type 1 with the gastrin receptor antagonist netazepide (YF476) results in regression of tumours and normalisation of serum chromogranin A. Aliment Pharmacol Ther 36:1067–1075

    Article  CAS  PubMed  Google Scholar 

  21. Ravizza D, Fiori G, Trovato C et al (2007) Long-term endoscopic and clinical follow-up of untreated type 1 gastric neuroendocrine tumours. Dig Liver Dis 39:537–543

    Article  CAS  PubMed  Google Scholar 

  22. Hosoya Y, Fujii T, Nagai H et al (1999) A case of multiple gastric carcinoids associated with multiple endocrine neoplasia type 1 without hypergastrinemia. Gastrointest Endosc 50:692–695

    Article  CAS  PubMed  Google Scholar 

  23. Debelenko LV, Emmert-Buck MR, Zhuang Z et al (1997) The multiple endocrine neoplasia type I gene locus is involved in the pathogenesis of type II gastric carcinoids. Gastroenterology 113:773–781

    Article  CAS  PubMed  Google Scholar 

  24. Tomassetti P, Migliori M, Caletti GC et al (2000) Treatment of type II gastric carcinoid tumors with somatostatin analogues. N Engl J Med 343:551–554

    Article  CAS  PubMed  Google Scholar 

  25. Hosoya Y, Nagai H, Koinuma K et al (2003) A case of aggressive neuroendocrine carcinoma of the stomach. Gastric Cancer 6:55–59

    Article  PubMed  Google Scholar 

  26. Kloppel G, Clemens A (1996) The biological relevance of gastric neuroendocrine tumors. Yale J Biol Med 69:69–74

    PubMed Central  CAS  PubMed  Google Scholar 

  27. Bordi C, Falchetti A, Azzoni C et al (1997) Aggressive forms of gastric neuroendocrine tumors in multiple endocrine neoplasia type I. Am J Surg Pathol 21:1075–1082

    Article  CAS  PubMed  Google Scholar 

  28. Rindi G, Kloppel G (2004) Endocrine tumors of the gut and pancreas tumor biology and classification. Neuroendocrinology 80(Suppl 1):12–15

    Article  CAS  PubMed  Google Scholar 

  29. Scherubl H, Cadiot G, Jensen RT et al (2010) Neuroendocrine tumors of the stomach (gastric carcinoids) are on the rise: small tumors, small problems? Endoscopy 42:664–671

    Article  CAS  PubMed  Google Scholar 

  30. Namikawa T, Oki T, Kitagawa H et al (2013) Neuroendocrine carcinoma of the stomach: clinicopathological and immunohistochemical evaluation. Med Mol Morphol 46:34–40

    Article  CAS  PubMed  Google Scholar 

  31. Klimstra DS, Modlin IR, Coppola D et al (2010) The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas 39:707–712

    Article  PubMed  Google Scholar 

  32. Nikou GC, Toubanakis C, Moulakakis KG et al (2011) Carcinoid tumors of the duodenum and the ampulla of Vater: current diagnostic and therapeutic approach in a series of 8 patients. Case series. Int J Surg 9:248–253

    Article  PubMed  Google Scholar 

  33. Capella C, Riva C, Rindi G et al (1990) Endocrine tumors of the duodenum and upper jejunum. A study of 33 cases with clinico-pathological characteristics and hormone content. Hepatogastroenterology 37:247–252

    CAS  PubMed  Google Scholar 

  34. Mullen JT, Wang H, Yao JC et al (2005) Carcinoid tumors of the duodenum. Surgery 138:971–977; discussion 977–978

    Article  PubMed  Google Scholar 

  35. Soga J (2003) Endocrinocarcinomas (carcinoids and their variants) of the duodenum. An evaluation of 927 cases. J Exp Clin Cancer Res 22:349–363

    CAS  PubMed  Google Scholar 

  36. Pipeleers-Marichal M, Somers G, Willems G et al (1990) Gastrinomas in the duodenums of patients with multiple endocrine neoplasia type 1 and the Zollinger-Ellison syndrome. N Engl J Med 322:723–727

    Article  CAS  PubMed  Google Scholar 

  37. Pipeleers-Marichal M, Donow C, Heitz PU et al (1993) Pathologic aspects of gastrinomas in patients with Zollinger-Ellison syndrome with and without multiple endocrine neoplasia type I. World J Surg 17:481–488

    Article  CAS  PubMed  Google Scholar 

  38. Kolby L, Nilsson O, Ahlman H (2004) Gastroduodenal endocrine tumours. Scand J Surg 93:317–323

    CAS  PubMed  Google Scholar 

  39. Park MI (2013) Endoscopic treatment for early foregut neuroendocrine tumors. Clin Endosc 46:450–455

    Article  PubMed Central  PubMed  Google Scholar 

  40. Zyromski NJ, Kendrick ML, Nagorney DM et al (2001) Duodenal carcinoid tumors: how aggressive should we be? J Gastrointest Surg 5:588–593

    Article  CAS  PubMed  Google Scholar 

  41. Burke AP, Sobin LH, Federspiel BH et al (1990) Carcinoid tumors of the duodenum. A clinicopathologic study of 99 cases. Arch Pathol Lab Med 114:700–704

    CAS  PubMed  Google Scholar 

  42. Eltawil KM, Gustafsson BI, Kidd M et al (2010) Neuroendocrine tumors of the gallbladder: an evaluation and reassessment of management strategy. J Clin Gastroenterol 44:687–695

    PubMed  Google Scholar 

  43. Yamamoto M, Nakajo S, Miyoshi N et al (1989) Endocrine cell carcinoma (carcinoid) of the gallbladder. Am J Surg Pathol 13:292–302

    Article  CAS  PubMed  Google Scholar 

  44. Albores-Saavedra J, Nadji M, Henson DE et al (1986) Intestinal metaplasia of the gallbladder: a morphologic and immunocytochemical study. Hum Pathol 17:614–620

    Article  CAS  PubMed  Google Scholar 

  45. Sasatomi E, Nalesnik MA, Marsh JW (2013) Neuroendocrine carcinoma of the extrahepatic bile duct: case report and literature review. World J Gastroenterol 19:4616–4623

    Article  PubMed Central  PubMed  Google Scholar 

  46. Pape UF, Perren A, Niederle B et al (2012) ENETS Consensus Guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas. Neuroendocrinology 95:135–156

    Article  CAS  PubMed  Google Scholar 

  47. Strosberg J (2012) Neuroendocrine tumours of the small intestine. Best Pract Res Clin Gastroenterol 26:755–773

    Article  CAS  PubMed  Google Scholar 

  48. Ahmed A, Turner G, King B et al (2009) Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study. Endocr Relat Cancer 16:885–894

    Article  CAS  PubMed  Google Scholar 

  49. Helland SK, Prosch AM, Viste A (2006) Carcinoid tumours in the gastrointestinal tract–a population-based study from Western Norway. Scand J Surg 95:158–161

    CAS  PubMed  Google Scholar 

  50. Plockinger U, Rindi G, Arnold R et al (2004) Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology 80:394–424

    Article  CAS  PubMed  Google Scholar 

  51. Strosberg JR, Weber JM, Feldman M et al (2013) Prognostic validity of the American Joint Committee on Cancer staging classification for midgut neuroendocrine tumors. J Clin Oncol 31:420–425

    Article  PubMed  Google Scholar 

  52. Maggard MA, O’Connell JB, Ko CY (2004) Updated population-based review of carcinoid tumors. Ann Surg 240:117–122

    Article  PubMed Central  PubMed  Google Scholar 

  53. Tomioka K, Fukoe Y, Lee Y et al (2013) Primary neuroendocrine carcinoma of the appendix: a case report and review of the literature. Anticancer Res 33:2635–2638

    PubMed  Google Scholar 

  54. Grozinsky-Glasberg S, Alexandraki KI, Barak D et al (2013) Current size criteria for the management of neuroendocrine tumors of the appendix: are they valid? Clinical experience and review of the literature. Neuroendocrinology 98:31–37

    Article  CAS  PubMed  Google Scholar 

  55. Holt N, Gronbaek H (2013) Goblet cell carcinoids of the appendix. ScientificWorldJournal 2013:543696

    Article  PubMed Central  PubMed  Google Scholar 

  56. Lawrence B, Gustafsson BI, Chan A et al (2011) The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am 40:1–18, vii

    Article  PubMed  Google Scholar 

  57. Modlin IM, Lye KD, Kidd M (2003) A 5-decade analysis of 13,715 carcinoid tumors. Cancer 97:934–959

    Article  PubMed  Google Scholar 

  58. Ramage JK, Goretzki PE, Manfredi R et al (2008) Consensus guidelines for the management of patients with digestive neuroendocrine tumours: well-differentiated colon and rectum tumour/carcinoma. Neuroendocrinology 87:31–39

    Article  CAS  PubMed  Google Scholar 

  59. West NE, Wise PE, Herline AJ et al (2007) Carcinoid tumors are 15 times more common in patients with Crohn’s disease. Inflamm Bowel Dis 13:1129–1134

    Article  CAS  PubMed  Google Scholar 

  60. Boudreaux JP, Klimstra DS, Hassan MM et al (2010) The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and Cecum. Pancreas 39:753–766

    Article  PubMed  Google Scholar 

  61. Mandair D, Caplin ME (2012) Colonic and rectal NET’s. Best Pract Res Clin Gastroenterol 26:775–789

    Article  PubMed  Google Scholar 

  62. Caplin M, Sundin A, Nillson O et al (2012) ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: colorectal neuroendocrine neoplasms. Neuroendocrinology 95:88–97

    Article  CAS  PubMed  Google Scholar 

  63. Tsikitis VL, Wertheim BC, Guerrero MA (2012) Trends of incidence and survival of gastrointestinal neuroendocrine tumors in the United States: a seer analysis. J Cancer 3:292–302

    Article  PubMed Central  PubMed  Google Scholar 

  64. Ito T, Sasano H, Tanaka M et al (2010) Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol 45:234–243

    Article  PubMed  Google Scholar 

  65. Yoon SN, Yu CS, Shin US et al (2010) Clinicopathological characteristics of rectal carcinoids. Int J Colorectal Dis 25:1087–1092

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey

    Ece Esin MD & Tugba Akin Telli MD

  2. Medical Oncology Department, Cancer Institute, Hacettepe University, Sihhiye, Ankara, Turkey

    Suayib Yalcin MD

Authors
  1. Ece Esin MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tugba Akin Telli MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Suayib Yalcin MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ece Esin MD .

Editor information

Editors and Affiliations

  1. Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey

    Suayib Yalcin

  2. Department of Endocrine Oncology, Uppsala University Hospital, Uppsala, Sweden

    Kjell Öberg

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Esin, E., Telli, T.A., Yalcin, S. (2015). Overview of Gastrointestinal Neuroendocrine Tumours. In: Yalcin, S., Öberg, K. (eds) Neuroendocrine Tumours. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-45215-8_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-45215-8_11

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-45214-1

  • Online ISBN: 978-3-662-45215-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation